ClinTec Launches Global Academy of Clinical Research Excellence Focusing on Training Clinical Professionals
News Jun 08, 2010
ClinTec International announces the opening of its Global Academy of Clinical Research Excellence “ACRE”, at the 2010 PABME (Pharmaceutical and Biotechnology Middle East) conference in Dubai, UAE.
The ACRE training courses which have been accredited by the Dubai Health Authority have admitted the first students for training in ICH-GCP. The academy is set to provide the MENA region with a significant resource for training and educating professionals in clinical research techniques, methods and practices. The academy’s mission is to accelerate knowledge growth and to increase the level and quality of clinical research carried out in Middle East.
ClinTec has individually recruited and selected the academy’s staff. With plans to roll-out academies in other emerging markets such as India, China and Latin America, staff at ACRE have been selected for their local knowledge and understanding of the local clinical research market and its specific needs.
Dr Rabinder Buttar, CEO of ClinTec International commented: “A major healthcare challenge in the MENA region has been the capacity to develop the knowledge of local investigators to levels in which they fully understand the complex nuances required in international clinical trials. The most effective way to make clinical research more meaningful is to have a thorough knowledge of the processes and procedures involved in research. Our experience has shown that cultivating a learning curve is imperative for professional success.”
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE